Abstract

Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy

Author(s): Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C

Issue: Jan/Feb 2019 - Volume 23, Number 1

Page(s): 77-81

Download in electronic PDF format for $75
  • Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 1
  • Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 2
  • Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 3
  • Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 4
  • Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 5

Abstract

The purpose of this study was to evaluate the transmucosal permeation of progesterone and testosterone using Pentravan as its vehicle for vaginal delivery. Progesterone deficiency is a hormone imbalance that could lead to luteal-phase deficiency, which is a common problem in assisted reproductive technologies. Testosterone has been explored for treating postmenopausal symptoms, such as vaginal atrophy. The ex vivo experiments were performed using porcine vaginal mucosa and phosphate buffered saline + 0.5% 2-hydroxypropyl-ß-cyclodextrin as the receptor media, which was later quantified through high-performance liquid chromatography. The percentage of the permeated drug was 0.4% and 20.3% for progesterone and testosterone, respectively. The permeation studies revealed that testosterone formulated with Pentravan is potentially effective in reaching the bloodstream and acts locally, whereas progesterone was mostly retained in the mucosa.

Related Keywords

  • progesterone
  • testosterone
  • intravaginal administration
  • vaginal preparation
  • transmucosal permeation
  • vaginal atrophy
  • formulation
  • luteal phase deficiency
  • menopausal women
  • liposomal vehicle

Related Categories

  • FORMULATIONS
  • HRT
  • PEER-REVIEWED
  • DOSAGE FORMS/DRUG CARRIERS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2019
Pg. 77-81
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy
Author(s): Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C
Nov/Dec 2018
Pg. 456-465
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome
Author(s): Riepl Mike
Nov/Dec 2009
Pg. 556
Gentian Violet Vaginal Suppositories
Author(s): Allen Loyd V Jr
Jan/Feb 2024
Pg. 58
Estradiol 0.1% Vaginal Solution
Author(s): Allen Loyd V Jr
Sep/Oct 2008
Pg. 450
Estradiol 0.1% Vaginal Solution
Author(s): Allen Loyd V Jr
Jul/Aug 2009
Pg. 338
Mupirocin 1% (20-mg) Vaginal Suppository
Author(s): Allen Loyd V Jr
Mar/Apr 2023
Pg. 108-112
Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study
Author(s): Lima Ramona, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
May/Jun 2018
Pg. 196-202
Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications
Author(s): Agbi Kelechi E, Hover Sara, Carvalho Maria
Jul/Aug 2016
Pg. 322
Nystatin 100,000-units Vaginal Inserts
Author(s): Allen Loyd V Jr
May/Jun 2017
Pg. 238
Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases
Author(s): Allen Loyd V Jr
Jul/Aug 2009
Pg. 334
Clindamycin 100-mg Vaginal Suppositories
Author(s): Allen Loyd V Jr
Jan/Feb 2024
Pg. 63
Progesterone Vaginal Suppositories (Fatty Acid Base)
Author(s): Allen Loyd V Jr
Jan/Feb 1998
Pg. 58
Progesterone 3% Vaginal Gel
Author(s): Allen Loyd V Jr
Jan/Feb 1998
Pg. 64
Progesterone Vaginal Cream (5%)
Author(s): Allen Loyd V Jr
Jan/Feb 1998
Pg. 65
Progesterone Vaginal Suppositories (Fatty Acid Base)
Author(s): Allen Loyd V Jr
Jan/Feb 1998
Pg. 66
Progesterone Vaginal Suppositories (Polyethylene Glycol Bases)
Author(s): Allen Loyd V Jr
Nov/Dec 2000
Pg. 464
Testosterone 1-mg/0.1-mL Topical Vaginal/Scrotal Spray
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 422-426
Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Author(s): Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli
Jul/Aug 2009
Pg. 314-317
Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Author(s): Glaser Rebecca L, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Nov/Dec 2018
Pg. 466-468
Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Author(s): Needham Shawn, Needham Shane